EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> E-Therapeutics (ETX) struck agreements with Intellegens and Biorelate to access artificial intelligence tools. Pilot studies suggest the tools complement ETX’s computational drug discovery technology. Statement

> ValiRx presented an analysis of data from a phase 2 trial of cancer candidate VAL401. Release 

> Avacta and Glythera entered into a licensing agreement. The signing of the deal follows an initial study to evaluate the use of Avacta's Affimer technology with Glythera's conjugation chemistry. Statement

> British trade group The BioIndustry Association secured clearance to intervene in a Supreme Court patent case. The BIA is concerned the court’s ruling could affect how much data and evidence companies need to patent inventions. Release

> Transgene’s China joint venture dosed the first hepatitis B patient in a phase 1 trial. Statement

> TxCell snagged a government loan to support preclinical development of its lead CAR-Treg program. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.